Literature DB >> 25735367

Inflammatory breast cancer in Tunisia from 2005 to 2010: epidemiologic and anatomoclinical transitions from published data.

N Mejri1, H Boussen, S Labidi, H Bouzaiene, M Afrit, F Benna, K Rahal.   

Abstract

AIM: To report epidemiologic and anatomoclinical transitions of inflammatory breast cancer (IBC) in Tunisia.
MATERIALS AND METHODS: Data including clinico-pathological data for208 cases of T4d or PEV 3 non-metastatic breast cancer diagnosed between 2005 and 2010 were collected from patient records. Chi2 and Z tests were used to compare variables with two Tunisian historical series and a series about Arab-American patients.
RESULTS: Thirty three percent of our patients had their first child before 23 years of age and 56% had their menarche before 12 years, 75% never receiving oral contraception. Obesity was observed in 42% of women and IBC occurred during pregnancy in 13% of cases. Tumor grade was II-III in 90% of cases, HR was negative in 52%, HER2 was over expressed in 31% and invasion of more than 3 axillary nodes occurred in 18% of patients. We observed a pCR rate of 19% after neoadjuvant treatment (anthracyline-taxane used in 79%, trastuzumab in 27% ). Compared to historical Tunisian series (since 1996), IBC epidemiology remained stable in terms of median age, menopausal status and obesity. However we observed a significant decrease in median clinical tumor size and number of positive axillary lymph nodes. Comparison to IBC in Arab-Americans showed a significant difference in terms of median age, menopausal status, positivity of hormonal receptors and educational level.
CONCLUSIONS: Our assessment of epidemiologic transition showed a reduction of clinco-pathological stage of IBC, keeping the same characteristics as compared to Tunisian historical series over a period of 14 years. Features seem to be different in Arab-American patients, probably related to migration, "occidentalization" of life style and improvement in socio-economic level.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25735367     DOI: 10.7314/apjcp.2015.16.3.1277

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

1.  Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).

Authors:  Meriem Slaoui; Abdou Azaque Zoure; Fatima Zahra Mouh; Youssef Bensouda; Mohammed El Mzibri; Youssef Bakri; Mariam Amrani
Journal:  BMC Cancer       Date:  2018-07-05       Impact factor: 4.430

2.  Association between epidemiological and clinico-pathological features of breast cancer with prognosis, family history, Ki-67 proliferation index and survival in Tunisian breast cancer patients.

Authors:  Najah Mighri; Nesrine Mejri; Maroua Boujemaa; Yosra Berrazega; Haifa Rachdi; Houda El Benna; Soumaya Labidi; Farouk Benna; Samir Boubaker; Hamouda Boussen; Sonia Abdelhak; Yosr Hamdi
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

3.  Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Authors:  Gerald Goh; Ramona Schmid; Kelly Guiver; Wichit Arpornwirat; Imjai Chitapanarux; Vinod Ganju; Seock-Ah Im; Sung-Bae Kim; Arunee Dechaphunkul; Jedzada Maneechavakajorn; Neil Spector; Thomas Yau; Mehdi Afrit; Slim Ben Ahmed; Stephen R Johnston; Neil Gibson; Martina Uttenreuther-Fischer; Javier Herrero; Charles Swanton
Journal:  PLoS Med       Date:  2016-12-06       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.